国药一致
(000028)
| 流通市值：102.33亿 | | | 总市值：119.14亿 |
| 流通股本：5.26亿 | | | 总股本：6.12亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 36,266,356,011.93 | 17,823,409,770.31 | 73,415,858,423.13 | 55,124,490,690.34 |
| 营业收入 | 36,266,356,011.93 | 17,823,409,770.31 | 73,415,858,423.13 | 55,124,490,690.34 |
| 二、营业总成本 | 35,498,296,956.6 | 17,432,136,489.2 | 71,812,830,420.19 | 53,874,589,496.98 |
| 营业成本 | 32,623,961,184.23 | 16,048,355,305.97 | 65,575,391,355.23 | 49,344,552,244.9 |
| 税金及附加 | 91,658,914.39 | 46,449,417.86 | 186,308,472.54 | 138,886,408.14 |
| 销售费用 | 2,220,158,107.17 | 1,062,076,917.93 | 4,846,915,960.57 | 3,551,256,072.17 |
| 管理费用 | 488,780,363.94 | 239,432,364.39 | 1,001,267,356.4 | 703,403,641.94 |
| 研发费用 | 3,482,128.08 | 1,513,333.97 | 19,986,945.44 | 16,559,803.77 |
| 财务费用 | 70,256,258.79 | 34,309,149.08 | 182,960,330.01 | 119,931,326.06 |
| 其中:利息费用 | 70,181,014.55 | 33,327,843.81 | 194,497,657.99 | 131,316,934.07 |
| 其中:利息收入 | 15,435,111.48 | 5,687,522.18 | 46,952,873.74 | 37,578,395.86 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -7,058,447.12 | - | 3,128,755.42 | 3,229,489.96 |
| 加:投资收益 | 96,851,862.15 | 57,982,973.89 | 217,607,416.92 | 165,074,116.96 |
| 资产处置收益 | 533,367.37 | -1,263,766.11 | 7,956,341.59 | 10,041,538.38 |
| 资产减值损失(新) | -9,910,448.35 | -1,351,906.57 | -290,177,026.92 | -4,041,733.23 |
| 信用减值损失(新) | -36,162,549.04 | -87,134,015.27 | -88,647,612.06 | -141,688,297.12 |
| 其他收益 | 22,117,555.04 | 17,080,301.93 | 59,932,952.93 | 50,961,278.62 |
| 四、营业利润 | 834,430,395.38 | 376,586,868.98 | 1,512,828,830.82 | 1,333,477,586.93 |
| 加:营业外收入 | 4,749,489.06 | 2,699,410.36 | 20,084,581.99 | 13,512,458.6 |
| 减:营业外支出 | 11,795,016.11 | 2,425,750.61 | 23,893,084.14 | 29,335,203.47 |
| 五、利润总额 | 827,384,868.33 | 376,860,528.73 | 1,509,020,328.67 | 1,317,654,842.06 |
| 减:所得税费用 | 179,586,837.78 | 71,699,564.96 | 380,671,650.91 | 298,257,458.01 |
| 六、净利润 | 647,798,030.55 | 305,160,963.77 | 1,128,348,677.76 | 1,019,397,384.05 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 647,798,030.55 | 305,160,963.77 | 1,128,348,677.76 | 1,019,397,384.05 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 606,203,553.4 | 287,462,500.32 | 1,135,926,834.84 | 957,118,469.53 |
| 少数股东损益 | 41,594,477.15 | 17,698,463.45 | -7,578,157.08 | 62,278,914.52 |
| 扣除非经常损益后的净利润 | 598,874,143.25 | 280,052,547.6 | 1,095,695,722.62 | 923,019,047.69 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.99 | 0.52 | 2.04 | 1.72 |
| (二)稀释每股收益 | 0.99 | 0.52 | 2.04 | 1.72 |
| 八、其他综合收益 | -6,177.6 | - | 1,970,509.18 | -36,254.21 |
| 归属于母公司股东的其他综合收益 | -6,177.6 | - | 1,172,484.56 | -36,254.21 |
| 九、综合收益总额 | 647,791,852.95 | 305,160,963.77 | 1,130,319,186.94 | 1,019,361,129.84 |
| 归属于母公司股东的综合收益总额 | 606,197,375.8 | 287,462,500.32 | 1,137,099,319.4 | 957,082,215.32 |
| 归属于少数股东的综合收益总额 | 41,594,477.15 | 17,698,463.45 | -6,780,132.46 | 62,278,914.52 |
| 公告日期 | 2026-08-29 | 2026-04-30 | 2026-04-02 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |